Initiate Phase 1/2 trial expansion for OTO-413 in hearing loss
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021”
What we found
Evidence strength A What the grades mean
Otonomy initiated the Phase 1/2 trial expansion for OTO-413 in June 2021, which falls within the second quarter of 2021 deadline.
-
A Otonomy, Inc. 8-K filed 2021-08-04
“In June 2021, Otonomy initiated an expansion of the Phase 1/2 trial reported in December in order to support endpoint selection and powering for a more formal Phase 2 trial.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- OTO-413 Phase 1/2 trial expansion
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Otonomy, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C493566-023681 · Corrections policy